Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open Phase IIIb study of cyclophosphamide to eliminate CD4+CD25+ regulatory T cells in patients with advanced hepatocellular carcinoma
2006-002546-11Phase 3Completed
- Sponsor
- Medizinische Hochschule Hannover
- Start
- Jan 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of cyclophosphamide in hepatocellular carcinoma (HCC), sponsored by Medizinische Hochschule Hannover. Primary endpoints: Reduction in regulatory CD4+CD25+ T cells and Change in T-cell phenotype. Started Jan 2007; status: completed.
02
Drugs
cyclophosphamide
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2006-002546-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002546-11.